Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Disappointed By New Extension Of EU Signal Detection Pilot

EFPIA Says Further Extension Was Not Expected

Executive Summary

A further extension of the EU signal detection pilot means that certain drug sponsors must keep monitoring the EudraVigilance database on a continuous basis. Industry argues there is enough evidence that this activity brings no additional value, and that current requirements should be replaced with a more proportionate approach.

You may also be interested in...



EU To Tighten Up Some Pharmacovigilance Requirements

The European Commission is consulting on a range of proposals to overhaul a nine-year-old regulation on drug safety reporting procedures.

EU Safety Signal Detection Pilot Extended Again

The pilot phase of a European project on new safety signal notification requirements has been extended for a second time following inconclusive results. 

Wait For Benefits Of EudraVigilance Pilot Before Expanding To More EU Products, Says Pharma

Drug companies say that any decision on taking the EudraVigilance monitoring requirements into the next phase should only be made when there is clear evidence that it has improved patient safety.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel